Kornimate/medical-research-clean huggingface dataset:
outcomes after sacrocolpopexy with and without burch to prevent stress urinary incontinence in 3rd and 4th degree apical uterine prolapse

Conditions: Prolapse

Summary: urinary incontinence will develop after prolapse repair in approximately one quarter of patients with advanced pelvic organ prolapse who remain continent despite significant loss of anterior vaginal and pelvic organ support. many women with advanced pelvic organ prolapse who choose to undergo surgical management also choose to undergo continence surgery in order to prevent new onset urinary incontinence.


Eligibility criteria:
inclusion criteria: - women with 3rd and 4th degree apical prolapse exclusion criteria: * patients with previous failed surgical intervention * patients with medical disorders that may interfere with surgical interventions . * patients with apical prolapsed complaining of stress urinary incontinence
metabolomic profiling of racial disparity

Conditions: Adenoid Hypertrophy; Tonsillar Hypertrophy; Surgery

Summary: tonsillectomy ± adenoidectomy (t\&a) is one of the most common surgical operations with over 500,000 pediatric t\&as performed annually in the united states. unfortunately, despite advances in anesthetic and surgical techniques, moderate-severe post-tonsillectomy pain (ptp) remains a significant problem affecting up to 62% of children. ptp is thought to arise from pharyngeal mucosal inflammation, which produces local nerve irritation and pharyngeal muscle spasm. patient factors and surgical techniques also play major roles. race is an important phenotypic risk factor for moderately severe early ptp. the underlying molecular basis of this differential pain experience is presently unknown. this gap in knowledge means that therapies are poorly targeted and often unsuccessful. indeed, treatment options for ptp have not advanced substantively for many years. metabolomics provides novel opportunities to investigate common and unique "metabolic signature" of ptp through the analysis of low molecular weight compounds produced in response to tissue injury. therefore, the central themes of this proposal are that (1) ptp is a complex process that may be determined by molecular level factors such as preoperative systemic inflammation and metabolic profile, and (2) these molecular level factors may explain the excess burden of ptp among minority children. here the investigators seek to utilize a combined clinical, biological and untargeted metabolomics approach to identify candidate small and large serum molecules that may influence the frequency and severity of ptp in children across racial groups. this approach to exploring the molecular basis of ptp is novel and knowledge from the study should substantially enhance understanding of the mechanisms underlying pediatric ptp - and narrow the racial disparities in post-operative pain.


Eligibility criteria:
inclusion criteria: * consenting (or assenting) patients age 4-17yr and american society of anesthesiologist's (asa) physical status i-iii who are scheduled for elective tonsillectomy ± adenoidectomy (t\&a). exclusion criteria: * age \> 18 years old * children below 4 years of age because they are routinely admitted following t\&a in our institution and may not be able to clearly self-report their pain * children on chronic preoperative analgesic medications * children with cushing's syndrome, or nephrotic syndrome * children on chronic systemic steroids * children with concurrent surgical procedures that could prolong the duration of anesthesia and surgery * children that do not speak english or cannot self-report their pain after surgery (significant cognitive impairment, anticipated or unplanned postoperative endotracheal intubation, and sedation)
the evaluation of postoperative antibiotics in non-infected mandible fractures

Conditions: Jaw Fractures; Infection

Summary: the purpose of the study is to evaluate if postoperative antibiotic use in patients with mandible trauma reduce the risk of postoperative infections and does the benefit differ based on severity, soft tissue loss, other concomitant injuries, and medical problems

the purpose of this study is to evaluate the use of antibiotics postoperatively in non-infected mandible fractures compared to the lack of postoperative antibiotics in the same population. the first outcome measure is infection. evidence of infection includes persistent swelling, fever, recurrent swelling, erythema, and purulent discharge. the second outcome measure is no infection. absence of persistent swelling, fever, recurrent swelling, erythema, and purulent discharge. outcome measures will be assessed on follow-up visits: post op week 1, post op week 3, and post op week 6-8. latest follow-up is up to 8 weeks. if the subject presents with any of the above mentioned symptoms during the 8 week post-op period, the subject will be considered positive for infection. prospective randomized trial: control group will not receive any postoperative antibiotics other than what is accepted as preoperative prophylactic antibiotics as per current standards of care. trial groups will receive a single post-operative dose administration of unasyn 3g or clindamycin 600mg (for penicillin allergies), then the patients in the trial group will be switched to oral augmentin 875mg twice a day for 7 days (amoxicillin and clavulanic acid which is clinically interchangeable with unasyn), or oral clindamycin 150mg to 300mg four times a day for 7 days (for penicillin allergies). if the patient is discharged home prior to completing 7 days of oral antibiotic therapy, patient will receive prescription to finish the remaining doses of antibiotics for a total period of 7 days. the patient will follow up post op week 1, post op week 3, and post op week 6-8. latest follow-up is up to 8 weeks. patients will be monitored for any complications, including reaction to iv and oral antibiotics. patient will assessed after the one-time post-op iv antibiotic dose and during their follow-up visits at weeks 1, 3, and 6-8.

Eligibility criteria:
inclusion criteria: * all mandible fracture patients planned for open reduction and internal fixation (orif) exclusion criteria: * age - \< 18 years * pregnancy * fracture site - closed / non-dentate eg. condylar neck, edentulous * soft tissue injury - \> grade 4 (gsw) * allergic to all study drugs * medical problems 1. diabetes - hb a1c \> 10 2. immunologic compromise 3. on chemotherapy * interval - injury to surgery - \> 10days * already receiving antibiotics for 1. another wound eg. open fracture prophylaxis 2. documented / suspected infection * inability to provide informed consent.

Keywords: infection jaw fracture
early detection of mental disorders in adolescents with chronic pain: creation of a screening tool for use by the general practitioner

Conditions: Chronic Pain; Mental Disorder

Summary: this research aims to create a tool for detection of mental health disorders in adolescents with chronic pain. the first part is testing a screening questionnaire and comparing in with existing questionnaires. the second part involves two focus group with the adolescents aimed at recording their perception of the questionnaire.

first part : creation of a screening tool. after detailed interviews with chronic pain experts and bibliographic research, a screening tool for mental disorders in chronically painful adolescents has been designed for use by the general practitioner. this tool is composed of 10 questions, making up a score of 10 points. the tool will be compared to two screening tools used in different clinical contexts, the had scale and the rpps scale, in order to determine a positivity threshold. there is only one center participating in the research, the centre de la douleur et de la migraine de l'hôpital trousseau (trousseau hospital pain center). parents' consent is required for participation. for this assessment, the adolescents (between 10 and 18 years old) that see a doctor at the centre de la douleur, will be asked to fill up the questionnaires in the waiting room. the filling of the questionnaire takes a few minutes. at the end of the appointment, the doctor will read the questionnaire to check that all elements have been addressed during the appointment. second part : focus group on the questionnaire: 5 to 10 adolescents will participate in a discussion group lead by a paediatrician and a psychologist from the centre de la douleur de trousseau. two groups will be organized, the length of the group discussion being one hour. these focus groups will explore the adolescents' perception of the questionnaire and of different elements of the screening. the group will undergo full transcription. the verbatim will be anonymous and will be analysed through qualitative methods. the data will help designing a guidebook for the clinician explaining the main points in screening for mental disorders in chronic pain adolescent patients. a validation study for the screening tool will be eventually carried out after the completion of this preliminary study.

Eligibility criteria:
inclusion criteria: * patient from 10 to 18 years old * chronic pain (existing for more than 3 months or longer than tissue repair time) * first consultation in the service * collection of the written consent of the holders of parental authority and agreement of the adolescent * adolescents able to understand the questionnaire and the purpose of the study * affiliation to a social security scheme or beneficiary exclusion criteria: exclusion criteria : * decompensated physical or psychological pathology requiring urgent medical treatment * heavy psychological pathology preventing the adolescent's understanding of the study * patient benefiting from state medical aid

Keywords: chronic pain mental disorders
novel combinations in participants with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma

Conditions: Gastric Cancer

Summary: this is a phase ii, open-label, multi-drug, multi-centre study designed to assess the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity of novel combination therapies in participants with locally advanced unresectable or metastatic gastric or gej adenocarcinoma.

approximately 240 participants will be assigned across 6 substudies, with approximately 40 evaluable participants of the confirmed recommend dose by src for study intervention in each corresponding substudy.

Eligibility criteria:
inclusion criteria: * 18 years or older at the time of signing the icf. * body weight \> 35 kg. * previously untreated for unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. * has measurable target disease assessed by the investigator based on recist 1.1. * ecog ps zero or one. * life expectancy of at least 12 weeks. * adequate organ and bone marrow function. * has central lab confirmed claudin18.2 status at screening from archival tumour collected within past 24 months or from a fresh biopsy when substudy 3, substudy 4 or substudy 6 is open for recruitment. exclusion criteria: * participants with her2-positive (3+ by ihc, or 2+ by ihc and positive by in situhybridisation) or indeterminate gastric or gej carcinoma. * untreated or progressive cns metastatic disease, any leptomeningeal disease, or cord compression. * participants with ascites which cannot be controlled with appropriate interventions. * active infectious diseases, including tuberculosis, hiv infection, or hepatitis a/b/c. * uncontrolled intercurrent illness. * active or prior documented autoimmune or inflammatory disorders requiring systemic treatment with steroids or other immunosuppressive treatment. * history of another primary malignancy. * previous treatment with an immune-oncology agent. * previous treatment with any modalities of claudin18.2 target therapy or mmae exposure (when substudy 3, substudy 4, or substudy 6 is open for recruitment).

Keywords: locally advanced metatstatic gastric adenocarcinoma gej adenocarcinoma gemini-gastric
anlotinib after chemoradiotherapy in stage iii non-small-cell lung cancer（alter-l029）

Conditions: Non-Small Cell Lung Cancer Stage III

Summary: evaluate the efficacy and safety of anlotinib following concurrent chemoradiation in patients with stage iii unresectable non-small cell lung cancer

anlotinib (al3818) is a kind of innovative medicines approved by state food and drug administration（sfda:2011l00661） which was researched by jiangsu chia-tai tianqing pharmaceutical co., ltd. anlotinib is a kinase inhibitor of receptor tyrosine with multi-targets, especially for vegfr1、vegfr2、vegfr3、fgfr1/2/3、pdgfra/β c-kit and met.

Eligibility criteria:
inclusion criteria: * 1.age at least 18 years. * 2.documented evidence of nsclc (locally advanced, unresectable, stage iii). * 3.patients must have received at least 2 cycles of platinum-based chemotherapy concurrent with radiation therapy. * 4.ecog ps : 0 to 1. * 5.estimated life expectancy of more than 12 weeks. exclusion criteria: * 1.prior exposure to any anti-angiogenesis drugs. * 2.central lung carcinoma along with large vessels or tumor with cavum or necrosis. * 3.evidence of severe or uncontrolled systemic diseases, including active bleeding diatheses or active infections including hepatitis b, c and hiv. * 4.any unresolved toxicity ctcae \>grade 2 from the prior chemoradiation therapy. * 5.evidence of uncontrolled illness such as symptomatic congestive heart failure, uncontrolled hypertension or copd.
inhalation of vapor with medication (diclofenac sodium, menthol, methyl salicylate and n-acetyl cysteine) reduces oxygen need and hospital stay in covid-19 patients - a case control study

Conditions: Covid19

Summary: background: in the midst of the devastating covid pandemic where there is no specific and effective treatment, traditional therapy may help to ease the patient's suffering. inhalation of vapor (vp) is an essential home remedy for stuffy, running nose in common cold, influenza and sinusitis. steam inhalation is helpful in destroying the capsid of the sars-cov-2 envelope and preventing infection. vapor with diclofenac sodium, menthol, methyl salicylate and n-acetyl cysteine may augment this effect. objective: to evaluate the effect of inhalation of vapor with medication and to compare with inhalation of vapor without medication. methods and materials: a case control study taken place in corona unit, sher-e-bangla medical college hospital, barishal. 43 patients with mild to moderate covid-19 were participated in this study. all are rt-pcr positive cases. among them 16 patients were in control group and 27 in study group. in study group they were given vapor with diclofenac sodium, menthol, methyl salicylate and n-acetyl cysteine and control group they were given normal steam/aquatic vapor two times in a day.


Eligibility criteria:
inclusion criteria: * patient must be covid 19 positive and having a lack of oxygen saturation. exclusion criteria: * all the patients who do not covid infected.

Keywords: vapor rt-pcr oxygen saturation
heart sounds registry

Conditions: Heart Failure; With Decompensation

Summary: to conduct a prospective, observational study to evaluate the non-interventional feasibility of using heart sounds measurements recorded by the lifevest® wearable cardioverter defibrillator (wcd) for monitoring clinical evidence of heart failure decompensation.

to conduct a prospective, observational study to evaluate the non-interventional feasibility of using heart sounds measurements recorded by the lifevest® wearable cardioverter defibrillator (wcd) for monitoring clinical evidence of heart failure decompensation. participants will be adult (age ≥ 18 years) heart failure patients with an ejection fraction (ef) ≤ 35% and eligible to wear the wcd for at least 3 months. an fda-approved wcd will be prescribed for at least 3 months of use after hospital discharge. this is a multi-center, prospective, observational study. the study will enroll a total of 300 subjects, anticipating that at least 250 subjects will complete the study. a maximum of 50 sites will enroll patients into the study.

Eligibility criteria:
inclusion criteria: * patients who are prescribed the wcd ≤ 10 days post-discharge after hospitalization with heart failure (hf), with and ischemic or non-ischemic cardiomyopathy. * patients who have an ejection fraction (ef) ≤ 35% at the time of wcd prescription. * patients are anticipated to wear the wcd for at least 3 months. * the subject must be 18 years of age or older on the day of screening. exclusion criteria: * patients with pacemakers, an implanted cardioverter defibrillator (icd), or a cardiac resynchronization therapy device. * patients waiting for heart transplant. * patients with known evidence of atrial fibrillation on their most recent ecg recording. * patients currently hospitalized for acute myocardial infarction. * patients with a planned revascularization within 30 days of screening. * patients who are self-reporting to be pregnant. * patients participating in another clinical study. * patients not expected to live longer than 1 year. * for patients in the united states, those who are unable or unwilling to provide written informed consent in english. * for patients in europe, those who are unable or unwilling to provide written informed consent in their country specific language or english.
remdesivir in adults with covid-19: mansoura university hospital experience

Conditions: Pneumonia, Viral

Summary: covid-19 is a respiratory disease caused by a new coronavirus (sars-cov-2) and causes significant morbidity and mortality. this study is a retrospective trial to assess the efficacy of remdesivir in adult patients diagnosed with covid-19 in mansoura university isolation hospital. in this study the investigators will analyze the data collected during treatment.

covid-19 is a novel respiratory disease caused by coronavirus (sars-cov-2) and results in significant morbidity and mortality. to date there is no approved medication for the treatment of patients with covid-19. remdesivir is a broad-spectrum antiviral nucleotide analogue that inhibits rna-dependent rna polymerase activity among a diverse group of rna viruses. non-clinical and clinical data suggest that remdesivir may be useful for the treatment of covid-19. who has identified remdesivir as a candidate drug of interest to be studied in clinical trials. this retrospective study is designed to analyze the data collected during the routine care of patients who have benefited from this therapy.

Eligibility criteria:
inclusion criteria: 1. adult ≥ 18 years old. 2. sars-cov-2 infection confirmed. 3. patients having classical radiological lesions of covid-19 on x-ray chest or hrct chest. 4. hospitalized patients who received at least one administration of remdesivir therapy (dose: 200mg day one then 100mg daily for up to 10 days). exclusion criteria: 1. presences of chronic renal failure \> 4 stage, gfr \< 30ml/min. 2. alt/ast \> 5 times than normal values. 3. pregnant women.
examining the link between obesity, inflammation, and response to asthma medications

Conditions: Asthma; Obesity

Summary: asthma is a common, long-term disease that is caused by inflammation of the airways. inflammation also plays a role in obesity and may affect the way a person responds to asthma medication. this study will examine the relationship between obesity and inflammation and the effect they have on response to corticosteroid asthma medications.

asthma affects 20 million people in the united states. it can be caused by many factors, including exposure to tobacco smoke, infections, and other allergens. recent research suggests that there may be a relationship between obesity and asthma. it is not fully understood how these two conditions are linked, but inflammation may play a role. obesity-related inflammation may increase the risk of airway inflammation, thereby elevating the risk of developing asthma. increased inflammation related to obesity may also reduce the effectiveness of inhaled steroid asthma medications, including glucocorticoids. compared with people of normal weight, people who are overweight or obese may have a higher risk of developing glucocorticoid insensitivity, resulting in intolerance to glucocorticoid medications. the purpose of this study is to examine the effect that obesity has on glucocorticoid insensitivity and inflammation. this study will also examine differences in the response to asthma steroid medications between people who are overweight or obese and those who are not. this study will use previously collected data from participants in two clinical trials of the nhlbi-funded asthma clinical research network (acrn): the best adjustment strategy for asthma in long term (basalt) study (nct00495157) and the tiotropium bromide as an alternative to increased inhaled corticosteroid in patients inadequately controlled on a lower dose of inhaled corticosteroid (talc) study. there will be no additional study visits specifically for this study. researchers will examine blood samples collected at participants' first basalt or talc study visit to analyze levels of inflammation biomarkers (including tumor necrosis factor-alpha \[tnf-α\], interleukin-6 \[il-6\], and leptin) and proinflammatory cytokines levels, which influence glucocorticoid insensitivity. additional basalt and talc study data, including lung function, asthma symptoms, and asthma exacerbations, will also be analyzed.

Eligibility criteria:
inclusion criteria: participation in either the basalt or talc studies of the asthma clinical research network. inclusion and exclusion criteria are as determined by those studies, nct00495157, nct00565266.

Keywords: steroid resistance inflammation
a study of the use of oral posaconazole (pos) in the treatment of asymptomatic chronic chagas disease (p05267)

Conditions: Chagas Disease

Summary: this is a study to compare the efficacy of oral posaconazole to placebo for the treatment of asymptomatic chagas disease. the primary hypothesis of the study is that posaconazole 400 mg twice daily improves therapeutic response compared to placebo in participants with a diagnosis of asymptomatic chronic chagas disease.


Eligibility criteria:
inclusion criteria: - must have a positive serology result for trypanosoma cruzi on any 2 of 3 of the following tests: indirect immunofluorescence, indirect hemagglutination, or enzyme-linked immunoabsorbent assay (elisa) * must have a positive qualitative polymerase chain reaction (pcr) for trypanosoma cruzi * must have a normal 12-lead electrocardiogram (ecg) * must have a normal 2-d echocardiogram * must have no evidence of ventricular tachycardia on 24-hour holter monitoring * female participants of childbearing age must be using a medically accepted method of birth control before beginning study drug treatment and must agree to continue its use during the study, or must have been surgically sterilized * female participants of childbearing potential must have a negative serum beta-human chorionic gonadotropin (hcg) pregnancy test at screening and a negative urine pregnancy test at baseline or within 72 hours before the start of study drug exclusion criteria: * are breastfeeding, pregnant, or planning to become pregnant * body weight \<60 kg * have an immunodeficiency or are immunosuppressed * history of megacolon with obstipation or megaesophagus with severe swallowing impairment. * have previously received treatment with benznidazole or nifurtimox * known allergy/sensitivity to azoles * has aspartate aminotransferase (ast) or alanine aminotransferase (alt) levels greater than 2.5 times the upper limit of normal at screening * has serum creatinine \>2.5 mg/dl or 200 micromoles at screening * has a history of severe alcohol abuse within two years from screening * is taking any of the prohibited medication